Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JCELL IN PATIENTS WITH RETINITIS PIGMENTOSA

Ophthalmology
Mitul Mehta
A RANDOMIZED, MASKED, PLACEBOCONTROLLED ADAPTIVE PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF A SINGLE INTRAVITREAL INJECTION OF JCELL (FAMZERETCEL) FOR THE TREATMENT OF RETINITIS PIGMENTOSA (RP).
Retinitis Pigmentosa

Study Description

A Randomized, Masked, Sham-Controlled, Phase 2 Trial of the Safety of a Single Intravitreal Injection of

jCell (famzeretcel) for the Treatment of Retinitis Pigmentosa (RP)

Eligibility

  1. Clinical diagnosis of RP supported by at least 2 of the following clinical findings:

Loss of peripheral vision on formal visual field testing

Symptoms of night blindness or difficulty adjusting to dim light

OCT outer retinal atrophy consistent with RP

  1. Subject age between 18 years and 60 years at time of signing of consent.
  1. Willingness of subject to consent to testing for RP gene mutation typing, if not performed

previously with available results

Key

  1. Participation in any clinical trial of a drug intervention within the last 6 months, with the

exception of a N-acetyl cysteine (NAC) study.

  1. History of ocular treatment with any non-approved, experimental, investigational or

neuroprotectant therapy (systemic, topical, intravitreal) or device in either eye, including

previous jCyte clinical trials. Individuals with a history of N-acetyl cysteine (NAC) treatment

may take part in the study following a 7-day washout period (prior to Baseline testing).

  1. Subject is pregnant or intends to become pregnant less than 12 months after jCell injection.
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.